REG - OptiBiotix Health - Planned launch of OptiBiotix products with Boots

OptiBiotix HealthAnnouncement

22/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230922:nRSV2789Na&default-theme=true

RNS Number : 2789N  OptiBiotix Health PLC  22 September 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Planned launch of OptiBiotix products with Boots

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that it has reached agreement to launch its own brands of
SlimBiome®, GoFigure®, and Snacksmart® products online with Boots in Q1
2024 with a potential store launch in May 2024, subject to Boots instore
category rebuild.

 

Boots is one of the largest retailers in the UK and Ireland with 58,000
employees in 2,200 shops across the United Kingdom and Ireland and reported
revenues of £6.5bn in 2022.  Stores range from local pharmacies to large
health and beauty shops are primarily located on the high streets, in
airports, and in shopping centres. Boots, developed its multichannel and
ecommerce business (Boots.com) during the course of the pandemic with its
online store generating sales of £576m in 2022. Its online business
experienced its biggest Black Friday ever in November 2022, taking three
orders every second for 14 consecutive hours Boots' online business helps kick
off the year strongly (chargedretail.co.uk)
(https://www.chargedretail.co.uk/2023/01/05/boots-online/) and now accounts
for 18% of total retail sales.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to report the
planned launch of our SlimBiome®, GoFigure®, and Snacksmart® products
online with Boots in Q1 2024. This is a first step in building our brand
presence with major retailers to support brand awareness and sales growth.
OptiBiotix is now building a multichannel presence with major online (Amazon)
and in store retailers both nationally (Holland and Barrett, Boots) and
internationally (Apollo Pharmacies: India; Nahdi Pharmacies: Saudi Arabia)
which will increase brand credibility and awareness."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQFLFLXKLLBBK